JP2023542297A5 - - Google Patents
Info
- Publication number
- JP2023542297A5 JP2023542297A5 JP2023516483A JP2023516483A JP2023542297A5 JP 2023542297 A5 JP2023542297 A5 JP 2023542297A5 JP 2023516483 A JP2023516483 A JP 2023516483A JP 2023516483 A JP2023516483 A JP 2023516483A JP 2023542297 A5 JP2023542297 A5 JP 2023542297A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- sequence shown
- component
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20195872.5 | 2020-09-14 | ||
| EP20195872 | 2020-09-14 | ||
| EP20210671 | 2020-11-30 | ||
| EP20210671.2 | 2020-11-30 | ||
| EP21155814.3 | 2021-02-08 | ||
| EP21155814 | 2021-02-08 | ||
| EP21176373 | 2021-05-27 | ||
| EP21176373.5 | 2021-05-27 | ||
| PCT/EP2021/075184 WO2022053703A1 (en) | 2020-09-14 | 2021-09-14 | Heterologous prime boost vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023542297A JP2023542297A (ja) | 2023-10-06 |
| JP2023542297A5 true JP2023542297A5 (enExample) | 2024-09-24 |
Family
ID=77897647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516483A Pending JP2023542297A (ja) | 2020-09-14 | 2021-09-14 | 異種プライムブーストワクチン |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20220088162A1 (enExample) |
| EP (1) | EP4210734A1 (enExample) |
| JP (1) | JP2023542297A (enExample) |
| KR (1) | KR20230069956A (enExample) |
| CN (1) | CN116348137A (enExample) |
| AU (1) | AU2021341521A1 (enExample) |
| BR (1) | BR112023001864A2 (enExample) |
| CA (1) | CA3188236A1 (enExample) |
| CL (1) | CL2023000642A1 (enExample) |
| CO (1) | CO2023004596A2 (enExample) |
| CR (1) | CR20230155A (enExample) |
| DO (1) | DOP2023000053A (enExample) |
| EC (1) | ECSP23027542A (enExample) |
| IL (1) | IL300060A (enExample) |
| JO (1) | JOP20230056A1 (enExample) |
| MX (1) | MX2023002884A (enExample) |
| PE (1) | PE20240492A1 (enExample) |
| TW (1) | TW202227126A (enExample) |
| WO (1) | WO2022053703A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| PL3429618T3 (pl) | 2016-03-16 | 2024-07-01 | Amal Therapeutics Sa | Kombinacja modulatora immunologicznego punktu kontrolnego i kompleks zawierający peptyd penetrujący komórkę, cargo i agonistę peptydu tlr do zastosowania w medycynie |
| HUE067838T2 (hu) | 2016-09-21 | 2024-11-28 | Amal Therapeutics Sa | Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| WO2025257278A1 (en) | 2024-06-12 | 2025-12-18 | Boehringer Ingelheim International Gmbh | Immunogenic sequences |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080305120A1 (en) | 2004-06-17 | 2008-12-11 | Medimmune, Inc. | Immunogenic Compositions Comprising Hmgb 1 Polypeptides |
| DE102004034461B4 (de) | 2004-07-16 | 2008-02-07 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| ES2291071B1 (es) | 2005-06-13 | 2009-03-16 | Proyecto De Biomedicina Cima, S.L. | Agentes y metodos basados en el uso del dominio eda de la fibronectina. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| EP2323685A2 (en) | 2008-07-11 | 2011-05-25 | Medizinische Universität Innsbruck | Agonists of nr2f6 for immunosuppression |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| DE102008050860A1 (de) | 2008-10-08 | 2010-04-15 | Dorothee Von Laer | LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP2476440B1 (en) | 2009-09-11 | 2017-08-02 | Proyecto de Biomedicina Cima, S.L. | Therapeutic compositions for the treatment of hpv-induced diseases |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| WO2011101332A1 (en) | 2010-02-16 | 2011-08-25 | Proyecto De Biomedicina Cima, S.L. | Compositions based on the fibronectin extracellular domain a for the treatment of melanoma |
| US8999349B2 (en) | 2010-07-27 | 2015-04-07 | The Regents Of The University Of California | HMGB1-derived peptides enhance immune response to antigens |
| WO2012048190A1 (en) | 2010-10-08 | 2012-04-12 | Regents Of The University Of Minnesota | Annexin ii compositions and methods |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| WO2013102144A2 (en) | 2011-12-30 | 2013-07-04 | Halozyme, Inc. | Ph20 polypeptede variants, formulations and uses thereof |
| WO2013120073A1 (en) | 2012-02-09 | 2013-08-15 | Av Therapeutics, Inc. | Synthetic toll-like receptor-4 (tlr-4) agonist peptides |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| HUE067838T2 (hu) * | 2016-09-21 | 2024-11-28 | Amal Therapeutics Sa | Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére |
| TWI894135B (zh) * | 2019-01-25 | 2025-08-21 | 德商百靈佳殷格翰國際股份有限公司 | 編碼ccl21之重組棒狀病毒 |
-
2021
- 2021-09-14 MX MX2023002884A patent/MX2023002884A/es unknown
- 2021-09-14 JP JP2023516483A patent/JP2023542297A/ja active Pending
- 2021-09-14 CN CN202180062772.6A patent/CN116348137A/zh active Pending
- 2021-09-14 IL IL300060A patent/IL300060A/en unknown
- 2021-09-14 BR BR112023001864A patent/BR112023001864A2/pt unknown
- 2021-09-14 TW TW110134259A patent/TW202227126A/zh unknown
- 2021-09-14 CA CA3188236A patent/CA3188236A1/en active Pending
- 2021-09-14 US US17/474,240 patent/US20220088162A1/en not_active Abandoned
- 2021-09-14 CR CR20230155A patent/CR20230155A/es unknown
- 2021-09-14 AU AU2021341521A patent/AU2021341521A1/en active Pending
- 2021-09-14 PE PE2023001150A patent/PE20240492A1/es unknown
- 2021-09-14 KR KR1020237012084A patent/KR20230069956A/ko active Pending
- 2021-09-14 EP EP21773815.2A patent/EP4210734A1/en active Pending
- 2021-09-14 WO PCT/EP2021/075184 patent/WO2022053703A1/en not_active Ceased
-
2023
- 2023-03-07 CL CL2023000642A patent/CL2023000642A1/es unknown
- 2023-03-14 DO DO2023000053A patent/DOP2023000053A/es unknown
- 2023-03-14 JO JOJO/P/2023/0056A patent/JOP20230056A1/ar unknown
- 2023-04-13 CO CONC2023/0004596A patent/CO2023004596A2/es unknown
- 2023-04-14 EC ECSENADI202327542A patent/ECSP23027542A/es unknown
-
2025
- 2025-06-13 US US19/237,140 patent/US20250312428A1/en active Pending